Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
mTORC1/mTORC2 Inhibitor
MTI-31 is a potent inhibitor of mTORC1 and mTORC2, demonstrating high selectivity for mTOR with a Kd of 0.20 nM and over 5,000-fold selectivity against PIK3CA, PIK3CB, and PIK3G. It exhibits an IC50 of 39 nM in the LANCE assay for mTOR substrate phosphorylation in the presence of 100 μM ATP. This compound is valuable for research into breast cancer and other diseases involving aberrant mTOR signaling pathways. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-4 is a potent orally active pan-class I PI3K/mTOR inhibitor. It demonstrates enzymatic inhibition across PI3Kα, PI3Kγ, PI3Kδ, and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM, and 13.85 nM, respectively. This reagent is primarily utilized in cancer research to investigate the role of the PI3K/mTOR signaling pathway in tumorigenesis and therapeutic responses. -
mTOR Inhibitor
WYE-23 is a selective mTOR inhibitor with a reported IC50 of 0.45 nM against mTOR and 661 nM against PI3Kα. This compound exhibits significant antitumor activity, making it a valuable reagent for cancer research. It is particularly useful for studies investigating the role of mTOR signaling in tumorigenesis and therapeutic interventions targeting this pathway. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-11 is a potent oral inhibitor of the PI3K/mTOR signaling pathway, exhibiting IC50 values of 3.5 nM, 4.6 nM, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR, respectively. This compound effectively impairs the phosphorylation of AKT and S6 proteins, thereby modulating critical cellular processes. PI3K/mTOR Inhibitor-11 is valuable for cancer research, offering insights into therapeutic strategies targeting aberrant signaling in tumors. -
mTORC1 Inhibitor
RMC-4627 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of cell growth and proliferation. This compound has been shown to activate 4EBP1, leading to the downregulation of protein synthesis and subsequently inhibiting tumor growth. RMC-4627 is valuable for research applications focused on cancer biology and the elucidation of mTOR signaling pathways. -
mTOR Complex 1 Inhibitor
WRX606 is a selective inhibitor of the mTOR complex 1 (mTORC1), which effectively disrupts the phosphorylation of key mTORC1 substrates, including S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E binding protein (4E-BP1), with IC50 values of 10 nM and 0.27 μM, respectively. This compound demonstrates significant antitumor activity by suppressing tumor growth in mouse models without promoting metastasis. WRX606 is a valuable tool for research focused on exploring therapeutic strategies against cancer through mTORC1 inhibition. -
mTOR Inhibitor
mTOR inhibitor WYE-28 selectively targets the mammalian target of rapamycin (mTOR), exhibiting an IC50 of 0.08 nM. Additionally, it inhibits PI3Kα with an IC50 of 6 nM, demonstrating its potential for broader applications in cancer therapy and metabolic research. WYE-28 has a metabolic half-life (T1/2) of 13 minutes in nude mouse microsomes, making it a valuable reagent for studying mTOR signaling pathways and their implications in disease models. -
mTOR Inhibitor
(32-Carbonyl)-RMC-5552 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), effectively blocking mTORC1 and mTORC2 signaling pathways. This compound impedes the phosphorylation of key substrates including p-P70S6K-(T389), p-4E-BP1-(T37/36), and p-AKT1/2/3-(S473), with pIC50 values greater than 9 for the first two and between 8 and 9 for the latter. (32-Carbonyl)-RMC-5552 is valuable for studies investigating mTOR-related cellular processes and the development of therapies targeting mTOR in various diseases. -
mTORC1/2 Inhibitor
AZD3147 is a potent, orally bioavailable dual inhibitor of mTORC1 and mTORC2, exhibiting an IC50 value of 1.5 nM. This compound selectively targets both complexes, while also having a specific inhibitory effect on PI3K. AZD3147 is primarily utilized in research related to cancer therapeutics and metabolic disorders, where modulation of the mTOR signaling pathway is of significant interest. -
mTOR Inhibitor
WYE-687 dihydrochloride is an ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR), demonstrating an IC50 of 7 nM. This compound effectively inhibits the activation of both mTORC1 and mTORC2, making it a valuable tool for studying mTOR signaling pathways. Additionally, WYE-687 modulates PI3Kα and PI3Kγ activity with IC50 values of 81 nM and 3.11 μM, respectively, supporting its role in cancer and metabolic research. -
PI3K/mTOR Inhibitor
DS-7423 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 15.6 nM for PI3Kα and 34.9 nM for mTOR. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research into cancer biology and potential therapeutic strategies. Its ability to inhibit key signaling pathways involved in cell growth and survival positions DS-7423 as a promising candidate for further exploration in oncology studies. -
PI3K/mTOR Inhibitor
PI3K-IN-37 is a potent inhibitor of the PI3K family, specifically targeting PI3K α, β, and δ isoforms with IC50 values of 6, 8, and 4 nM, respectively. Additionally, PI3K-IN-37 demonstrates strong inhibition of mTOR with an IC50 of 4 nM. This compound is valuable for research applications involving cancer biology, metabolic disorders, and signaling pathways related to cell growth and survival. -
PI3Kα/mTOR Kinase Inhibitor
PI3K-IN-22 is a potent dual inhibitor of the PI3Kα and mTOR kinases, with IC50 values of 0.9 nM and 0.6 nM, respectively. This compound exhibits substantial biological activity, making it valuable for investigating the roles of these pathways in cancer research. PI3K-IN-22 can facilitate the study of tumor growth and response to therapy, contributing to the understanding of oncogenic signaling and potential treatment strategies. -
Dual PI3K/mTOR Inhibitor
PKI-179 hydrochloride is a potent dual inhibitor of the PI3K and mTOR signaling pathways, demonstrating IC50 values of 8 nM for PI3K-α, 24 nM for PI3K-β, 74 nM for PI3K-γ, 77 nM for PI3K-δ, and 0.42 nM for mTOR. This compound is effective against mutant variants E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride has been shown to exhibit significant anti-tumor activity in vivo, making it a valuable tool for cancer research and therapeutic development targeting PI3K/mTOR pathways. -
PI3K/mTOR Inhibitor
SN32976 is a potent and selective inhibitor of class I phosphoinositide 3-kinases (PI3K) and mTOR, exhibiting IC50 values of 15.1 nM for PI3Kα, 461 nM for PI3Kβ, 110 nM for PI3Kγ, 134 nM for PI3Kδ, and 194 nM for mTOR. This compound demonstrates significant selectivity against a wide panel of 442 kinases. SN32976 is primarily utilized in cancer research, showcasing notable anticancer activity that makes it a valuable tool for studying PI3K/mTOR pathway modulation. -
mTOR Inhibitor
MHY-1685 is a novel inhibitor of the mammalian target of rapamycin (mTOR), a key regulator of cell growth and metabolism. This compound demonstrates significant potential in promoting human cardiac stem cell (hCSC)-based myocardial regeneration. Its efficacy in modulating the mTOR pathway makes MHY-1685 a valuable tool for researchers investigating cardiac repair mechanisms and therapies. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-13 sodium is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mTOR kinase, demonstrating oral bioavailability. This compound exhibits significant biological activity in the modulation of cellular growth and metabolism, making it a valuable tool in research related to sexual dysfunction, solid tumors, and idiopathic pulmonary fibrosis (IPF). Its dual inhibition profile presents opportunities for therapeutic exploration in various disease contexts. -
PI3K/mTOR inhibitor
PI3K-IN-18 is a potent inhibitor of the PI3K/mTOR signaling pathway, selectively targeting PI3K-α and mTOR with IC50 values of 41 nM and 49 nM, respectively. This compound exhibits significant biological activity by disrupting key signaling processes involved in cell growth and proliferation. PI3K-IN-18 is valuable for research applications focused on cancer biology, metabolism, and therapeutic strategies targeting the PI3K/mTOR axis. -
mTORC1/2 Inhibitor
Dihydroevocarpine is a selective inhibitor of mTORC1 and mTORC2, exhibiting potent cytotoxic effects in acute myeloid leukemia cells. By effectively suppressing mTORC1/2 activity, it disrupts critical signaling pathways involved in cell proliferation and survival. This compound is valuable for research focused on cancer biology and the development of targeted therapies for hematological malignancies. -
PI3K Inhibitor
PI3Kα/mTOR-IN-1 is a selective dual inhibitor targeting PI3Kα and mTOR, exhibiting an IC50 of 7 nM for PI3Kα in cellular assays. It demonstrates Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in cell-free assays, respectively. This compound is instrumental in studies related to cancer biology and signal transduction, making it valuable for research involving the modulation of PI3K/mTOR pathways. -
mTORC Inhibitor
OXA-01 is a potent inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) and complex 2 (mTORC2), exhibiting IC50 values of 29 nM and 7 nM, respectively. This compound effectively disrupts mTOR signaling, which plays a crucial role in cellular growth, metabolism, and proliferation. OXA-01 is valuable for research applications investigating cancer, metabolic disorders, and the modulation of cellular signaling pathways. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-9 is a potent inhibitor targeting both the PI3K and mTOR pathways, exhibiting IC50 values of 38 nM for mTOR (in phospho-S6 cellular assays) and 6.6 μM, 6.6 μM, and 0.8 μM for PI3Kα, PI3Kγ, and PI3Kδ, respectively. This compound demonstrates significant biological activity in modulating cellular growth and metabolism, making it a valuable tool for research on cancer and other diseases characterized by dysregulated PI3K/mTOR signaling. Its application in various cellular models facilitates the exploration of therapeutic strategies in oncology and other fields of biomedical research. -
mTOR Inhibitor
mTOR inhibitor-23 (compound DHM25) is a selective and irreversible covalent inhibitor of the mechanistic target of rapamycin (mTOR). It functions through covalent interaction with a nucleophilic amino acid in the ATP binding pocket, effectively modulating mTOR signaling pathways. This compound demonstrates significant antitumor activity against triple-negative breast cancer cell lines, highlighting its potential in cancer research and therapeutic applications. -
mTOR Inhibitor
AV457 is a potent and selective inhibitor of the mTOR pathway, exhibiting an IC50 value of 0.54 µM. This compound has demonstrated efficacy in reducing cyst growth in organoids derived from polycystic kidney disease (PKD). Additionally, AV457 effectively lowers the protein expression levels of P-S6 and P-P70S6, while leaving P-AKT levels unchanged, making it a valuable tool for investigating mTOR-related signaling in various biological contexts. -
mTOR Inhibitor
mTOR inhibitor-12 is a selective inhibitor of the mechanistic target of rapamycin (mTOR) that effectively penetrates the blood-brain barrier. This compound demonstrates significant potential in modulating mTOR signaling pathways, making it valuable in the study of central nervous system (CNS) disorders. Additionally, mTOR inhibitor-12 has been assessed for its non-genotoxic properties, facilitating safer applications in neurological research. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-5 selectively targets both phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), demonstrating IC50 values of 86.9 nM for PI3K and 14.6 nM for mTOR. This dual inhibition has significant implications for cancer research, as it can effectively impede cell proliferation and survival in tumor cells. PI3K/mTOR Inhibitor-5 is suitable for studies investigating the PI3K/mTOR signaling pathway and its role in various diseases, particularly in the contexts of oncology and metabolic disorders. -
mTOR Inhibitor
PF-05139962 is a cyclic sulfone compound that acts as a potent inhibitor of the mTOR kinase. It demonstrates strong inhibitory activity with a Ki of 5 nM and IC50 values of 48 nM for phosphorylated S473 and 6 nM for phosphorylated S6, highlighting its high selectivity. This compound is valuable for research applications involving cell growth, metabolism, and cancer therapy, particularly in studies focused on mTOR signaling pathways. -
mTOR Inhibitor
RMC-4529 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), demonstrating an IC50 value of 1.0 nM against phosphorylated 4E-BP1 at threonine 37/46 in cellular assays. This compound is valuable for research applications focused on mTOR signaling pathways, potentially impacting studies in cancer, metabolism, and neurodegenerative diseases. Its selectivity and efficacy make it a useful tool for investigating the role of mTOR in various biological processes. -
mTOR Inhibitor
GNE-555 is a selective, metabolically stable inhibitor of the mechanistic target of rapamycin (mTOR), with a Ki value of 1.5 nM. This compound demonstrates significant antiproliferative effects on prostate cancer (PC3) and breast cancer (MCF-7) cell lines. GNE-555 is ideal for applications in cancer research, particularly in studies exploring mTOR signaling pathways and their role in tumorigenesis. -
mTOR Inhibitor
eCF309 is a potent and selective mTOR inhibitor, exhibiting an IC50 of 15 nM. This compound demonstrates heightened selectivity over PI3 kinases, making it a valuable tool for research. eCF309 is particularly relevant in the study of breast cancer and prostate cancer, facilitating investigations into the mechanistic roles of mTOR signaling in these diseases. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-3 is a potent dual inhibitor of phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). This imidazoline derivative exhibits significant anti-cancer activity, making it a valuable tool for cancer research. Its ability to modulate key signaling pathways related to cell growth and survival enhances its utility in studying tumor biology and therapeutic strategies. -
PI3Kα/mTOR Inhibitor
PI3Kα-IN-5 is a potent inhibitor of the PI3Kα and mTOR pathways, exhibiting IC50 values of 0.7 nM and 3.3 nM, respectively. This compound is valuable for research focused on colorectal cancer, offering insights into the modulation of these critical signaling pathways. Its specificity and efficacy make it an important tool for investigating the roles of PI3Kα and mTOR in cancer biology. -
mTOR Inhibitor
mTOR Inhibitor-11 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), exhibiting an IC50 of 21 nM for phosphorylated S6 ribosomal protein. This compound also demonstrates inhibitory activity against checkpoint kinase 1 (pCHK1) and phosphodiesterase 4D (PDE4D), with IC50 values of 17.2 μM and 17.0 μM, respectively. mTOR Inhibitor-11 is suitable for research on central nervous system (CNS) diseases, facilitating studies into neurodegenerative conditions and other related disorders. -
mTOR Inhibitor
PP30 is a potent, selective ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR), exhibiting an IC50 of 80 nM. This compound demonstrates significant inhibition of mTOR signaling, making it valuable for research focused on cell growth, proliferation, and survival pathways. PP30 is applicable in studies related to cancer, metabolic disorders, and various diseases involving dysregulation of mTOR pathways. -
mTORC1 Pathway Inhibitor
CIDD 0067106 is a selective inhibitor of the mTORC1 pathway, specifically designed for targeting androgen receptor-positive (AR+) triple-negative breast cancer (TNBC). It exhibits potent activity against AR+ TNBC cell lines, with a GI50 value of 0.8 μM, indicating its effectiveness in inhibiting cancer cell proliferation. This compound is valuable for research focused on understanding and developing treatments for AR+ TNBC. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-12 is a selective inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways, exhibiting IC50 values of 0.06 nM for PI3Kα and 3.12 nM for mTOR. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Additionally, PI3K/mTOR Inhibitor-12 has been shown to possess reduced liver toxicity, enhancing its potential for therapeutic applications in oncology. -
mTOR Inhibitor
PT-88 is a highly selective inhibitor of the mTOR (Mammalian Target of Rapamycin) pathway, demonstrating an IC50 of 1.2 nM. This compound effectively inhibits both mTORC1 and mTORC2 complexes, which play critical roles in regulating cell growth, proliferation, and survival. PT-88 is suitable for investigating the involvement of mTOR in tumorigenesis and development, particularly in breast cancer research. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-8 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. This compound promotes apoptosis in HCT-116 cells and effectively induces cell cycle arrest at the G1/S phase. It serves as a valuable tool for researchers investigating the roles of PI3K and mTOR signaling in cancer biology and potential therapeutic interventions. -
mTOR Inhibitor
YB-3-17 is a bifunctional PROTAC molecule that targets the mechanistic target of rapamycin (mTOR) with an IC50 of 0.22 nM and induces degradation of G1 to S phase transition 1 gene (GSPT1) with a DC50 of 5 nM. This compound demonstrates significant antiproliferative effects in various glioblastoma cell lines, achieving nanomolar IC50 values. Additionally, YB-3-17 exhibits notable antitumor efficacy in preclinical mouse models, making it a valuable tool for studying mTOR inhibition and its implications in cancer therapy. -
mTOR Inhibitor
CC214-1 is a potent mTOR inhibitor with an IC50 of 0.002 μM that induces autophagy. This compound serves as a valuable in vitro tool for investigating mTOR kinase biology. CC214-1 is particularly relevant for research in glioblastoma, providing insights into cancer cell metabolism and potential therapeutic strategies. -
PI3K Inhibitor
MCX 28 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, functioning as a triple inhibitor of PI3K, mTOR, and PIM kinases. It exhibits low nanomolar activity, making it a valuable tool for studying signaling pathways involved in cancer and other diseases. This compound is particularly useful for research applications focused on the modulation of cell proliferation, survival, and metabolic processes. -
mTOR-C1 Inhibitor
LGB321 is a selective mTOR-C1 inhibitor that effectively disrupts PIM2-dependent signaling pathways in multiple myeloma cell lines. This compound inhibits cell proliferation and modulates key cellular processes, including the phosphorylation of BAD. LGB321 is valuable for research focused on understanding the mechanisms of multiple myeloma and the mTOR signaling pathway. -
PI3K/mTOR Inhibitor
PI3K/mTOR-IN-18 is a highly selective dual inhibitor targeting PI3Kα and mTOR, with binding affinities of Ki=0.130 nM and Ki=0.111 nM, respectively. This compound effectively blocks the PI3K/AKT/mTOR signaling pathway, resulting in significant inhibition of tumor cell proliferation (IC50=144 nM). PI3K/mTOR-IN-18 is suitable for research involving various solid tumors, including breast cancer and non-small cell lung cancer (NSCLC). -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-14 is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), exhibiting IC50 values of 171.4 nM and 10.1 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its inhibition of the PI3K/mTOR signaling pathway can be critical for studies focused on cell proliferation and survival in various cancer models. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent dual inhibitor targeting the PI3K and mTOR pathways. It demonstrates a 4.7-fold increased potency compared to the positive control gedatolisib, with an IC50 of 0.3 μM. At a concentration of 10 μM, PI3K/mTOR Inhibitor-7 effectively suppresses the PI3K/Akt/mTOR signaling pathway. This compound is valuable for research applications focused on cancer biology and related therapeutic development. -
mTOR Inhibitor
mTOR inhibitor-18 is a selective inhibitor of the mechanistic target of rapamycin (mTOR). It exhibits significant activity in modulating intracellular signaling pathways associated with cell growth, proliferation, and survival. This compound is particularly useful in researching various conditions, including cancer, immune disorders, cardiovascular diseases, viral infections, inflammation, and metabolic or endocrine function disorders. Its role in neurological research further highlights its versatility as a critical tool in understanding mTOR-related biological processes. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-6 is a potent dual inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. This compound demonstrates enhanced stability in artificial gastric fluids compared to other PI3K/mTOR inhibitors. At a concentration of 10 μM, PI3K/mTOR Inhibitor-6 effectively suppresses the PI3K/Akt/mTOR signaling pathway, highlighting its potential for cancer research applications. -
mTOR Inhibitor
P-2281 is an mTOR inhibitor that exhibits significant anticancer and anti-inflammatory properties. It effectively inhibits mTOR activity in colon cancer cells and suppresses Dextran sulfate sodium salt (DSS)-induced colitis by modulating T cell function. P-2281 has demonstrated efficacy in murine models of human colitis, making it a valuable tool for research into cancer therapies and inflammatory bowel diseases. -
PI3K inhibitor
PI-540 is a bicyclic thienopyrimidine derivative that functions as an orally active inhibitor of phosphoinositide 3-kinases (PI3K). Demonstrating potent anti-cancer cell proliferation activity, PI-540 selectively inhibits various PI3K isoforms with IC50 values of 10 nM for P110α, 3510 nM for P110β, 410 nM for P110δ, and 33110 nM for P110γ. In addition to its PI3K inhibition, PI-540 also targets mTOR and DNA-PK, with IC50 values of 61 nM and 525 nM, respectively, making it a valuable tool for cancer research and therapeutic development. -
PI3K/mTOR Inhibitor
CC-M-1 is a potent and selective inhibitor of the PI3K/mTOR signaling pathway, targeting PI3Kα/β/γ/δ and mTOR with IC50 values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. This compound demonstrates significant inhibition of proliferation in colorectal cancer cell lines, including HCT-116 (IC50 = 0.38 μM) and HT-29 (IC50 = 1.70 μM). CC-M-1 serves as a valuable tool for researchers investigating colorectal cancer (CRC) therapeutic strategies and the underlying mechanisms of tumorigenesis.
